With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.... Jun 14
GSK gets FDA nod for Jemperli indicated for endometrial cancer... Apr 26
The FDA is granted accelerated approval to Jemperli (dostarlimab)) for treatment of patients with recurrent and advanced endometrial cancer that has progressed with the prior ... Apr 24
-Advertisements-